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Abstract
Background: Because of the possible role of cytokines including interleukins (IL) in systemic non-thyroidal illnesses' (NTI)
pathogenesis and consequently the frequently associated alterations in thyroid hormone (TH) concentrations constituting the
euthyroid sick syndrome (ESS), we aimed in this research to elucidate the possible relation between IL-6 & IL-10 and any
documented ESS in a cohort of patients with NTI.
Methods: Sixty patients and twenty healthy volunteers were recruited. The patients were subdivided into three subgroups
depending on their underlying NTI and included 20 patients with chronic renal insufficiency (CRI), congestive heart failure (CHF),
and ICU patients with myocardial infarction (MI). Determination of the circulating serum levels of IL-6 and IL-10, thyroid
stimulating hormone (TSH), as well as total T4 and T3 was carried out.
Results: In the whole group of patients, we detected a significantly lower T3 and T4 levels compared to control subjects (0.938
± 0.477 vs 1.345 ± 0.44 nmol/L, p = 0.001 and 47.9 ± 28.41 vs 108 ± 19.49 nmol/L, p < 0.0001 respectively) while the TSH level
was normal (1.08+0.518 μIU/L). Further, IL-6 was substantially higher above controls' levels (105.18 ± 72.01 vs 3.35 ± 1.18 ng/
L, p < 0.00001) and correlated negatively with both T3 and T4 (r = -0.620, p < 0.0001 & -0.267, p < 0.001, respectively). Similarly
was IL-10 level (74.13 ± 52.99 vs 2.64 ± 0.92 ng/ml, p < 0.00001) that correlated negatively with T3 (r = -0.512, p < 0.0001) but
not T4. Interestingly, both interleukins correlated positively (r = 0.770, p = <0.001). Moreover, IL-6 (R2 = 0.338, p = 0.001) and
not IL-10 was a predictor of low T3 levels with only a borderline significance for T4 (R2 = 0.082, p = 0.071).
By subgroup analysis, the proportion of patients with subnormal T3, T4, and TSH levels was highest in the MI patients (70%,
70%, and 72%, respectively) who displayed the greatest IL-6 and IL-10 concentrations (192.5 ± 45.1 ng/L & 122.95 ± 46.1 ng/L,
respectively) compared with CHF (82.95 ± 28.9 ng/L & 69.05 ± 44.0 ng/L, respectively) and CRI patients (40.05 ± 28.9 ng/L &
30.4 ± 10.6 ng/L, respectively). Surprisingly, CRI patients showed the least disturbance in IL-6 and IL-10 despite the lower levels
of T3, T4, and TSH in a higher proportion of them compared to CHF patients (40%, 45%, & 26% vs 35%, 25%, & 18%,
respectively).
Conclusion: the high prevalence of ESS we detected in NTI including CRI may be linked to IL-6 and IL-10 alterations. Further,
perturbation of IL-6 and not IL-10 might be involved in ESS pathogenesis although it is not the only key player as suggested by
our findings in CRI.
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Background
Despite absence of thyroid disease, patients with non-thy-
roidal illness (NTI) frequently have changes in serum thy-
roid hormone (TH) measurements that may suggest
thyroid dysfunction. The clinical impression of euthy-
roidism is supported by normal serum thyroid stimulat-
ing hormone (TSH) in most of these patients [1]. Many of
the clinically euthyroid patients with NTI have low circu-
lating concentrations of total and absolute free triiodothy-
ronine (T3), low-normal concentrations of total thyroxine
(T4), elevated concentrations of absolute free T4, and nor-
mal or subnormal TSH [2] although Hesch (1981) has
reported simultaneous elevation of TSH to compensate
for these low levels. Consequently, the patients are usually
clinically euthyroid [3]. This was named the "euthyroid
sick syndrome" (ESS) [4] that have been described some
36 years ago [5].
The mechanisms accounting for such alterations in the TH
levels in association with NTI remain unknown despite
extensive investigations. The hope for the discovery of fac-
tor (s) responsible for such changes came with the obser-
vations that inflammatory cytokines are influential in
systemic diseases mediation [6]. More precisely, the
cytokine tumor necrosis factor-α (TNF-α) and interleukin-
1β (IL-1β) resulted in similar changes in TH concentra-
tions in experimental animals [7] and human volunteers
[8]. However, none of the two cytokines was consistently
detectable NTI-patients [9,10]. In contrast, IL-6 is usually
detectable in serum during illness and acts as a systemic
hormone [11] that may mediate the well documented
inhibitory effect of IL-1 on thyroid cell functions [12].
Interestingly, Shalaby and colleagues (1989) suggested IL-
6 as a potential factor in the pathogenesis of the ESS [13].
Although the pathogenesis of hypothalamic-pituitary-thy-
roid axis depression encountered in ESS remains elusive,
yet it is currently agreed that it may be related to increased
cytokines production [14,11,15] that induced competi-
tion for limiting amounts of co-activators and decreases
hepatocyte thyroxine 5' D-I deiodinase enzyme expres-
sion [16]. The inhibitory effect of IL-6 on thyroid function
may be through binding of IL-6-sIL-6R complex to gp130
[17].
In contrast to IL-6, IL-10 is one of the most potent anti-
inflammatory cytokines [18,19] and is produced by mac-
rophages as well as other cell types [20]. Interestingly, pro-
inflammatory stimuli like IL-1β and TNF-α enhance its
secretion without any influence of IL-6 [21].
We have carried out this cross-sectional observational
study to link thyroid function and the cytokines; IL-6 as
well as IL-10 in a group of patients with ESS associated
with variable NTI including chronic renal insufficiency
(CRI).
Methods
We have investigated serum samples collected from 60
patients (46 men, 14 women; aged 45 ± 19 years) who
were hospitalized because of a wide variety of NTI. The
patients were recruited to the planned study consecutively
in a random manner except those with known or clini-
cally suspected thyroid dysfunction. Additional exclusion
criteria were use of thyroid hormones or thyrostatic med-
ications. The patients were subdivided into 3 equal sub-
groups reflecting the nature of their NTI and include;
those with CRI, congestive heart failure (CHF), and
patients with acute myocardial infarction (MI). None of
the CRI patient was replaced by dialysis treatment as their
mean estimated glomerular filtration rate, using the
abbreviated 4 variable MDRD formula, was 27.6 ± 3 ml/
min/1.73 m2. The leading cause of their chronic renal
insufficiency was DM (30%), hypertension (25%),
glomerular disease (15%), obstructive nephropathy
(10%) and unknown in the remaining (20%). The sever-
ity of MI was assessed clinically as well as by the degree of
elevation of CK-MB isoenzyme. Twenty healthy volun-
teers (15 men, 5 women; aged 39 ± 5 years) were recruited
as control group. Samples from both patients and controls
were collected for measurement of serum IL-6, IL-10, TSH,
T3, and total T4 levels.
Both, the ultrasensitive human TSH (hTSH II) and free T3
were measured by a Microparticle Enzyme Immunoassay
(MEIA) on AxSYM System (Abbott Laboratories, Abbott
Park, USA) [22,23] while total serum T4 was measured by
the Fluorescence Polarization Immunoassay (FPIA)
method on AxSYM System [24] using the standard labora-
tory methodologies.
Serum IL-6 was measured using a commercially obtained
immunoassay (IL-6 Quantikin assay, R&D Systems,
Abingdon, UK) with a sensitivity of 0.7 ng/l and an intra-
and inter-assay CV of 3.2 and 5.7%, respectively. IL-6 ref-
erence values in fresh samples of healthy individuals are
20-12.5 ng/L. The serum level of IL-10 (Human IL-10
Quantikin ELISA immunoassay, R&D Systems Inc, Min-
neapolis, Minnesota, USA) was measured with an
expected value below 5 pg/ml and no cross-reactivity with
other interleukins including IL-6. The maximum inter-
and intra-assay CV were 9.8% and 5.6%, respectively.
Blood samples were taken between 7 AM and 9 AM after
an overnight fast. After centrifugation (1500 × g) for 10
minutes, aliquots of serum were stored at -20°C until the
time of sample analysis. Both interleukins were assessed
by competitive enzyme-linked immunosorbent assay
(ELISA) in serum of both patients' and control's accordingBMC Endocrine Disorders 2008, 8:1 http://www.biomedcentral.com/1472-6823/8/1
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to a method described by Helle and colleagues (1991)
using recombinant human cytokine as standard [25].
For the MI patients, the cardiac enzyme CK-MB isoenzyme
was measured (IU/L) as a rough indicator of myocardial
damage severity while the glomerular filtration rate was
estimated (eGFR) based on the abbreviated MDRD for-
mula:
eGFR (ml/min/1.73 m2) = 186 × {[sCr]-1.154} × age 
(years)-0.203 × 0.742 if Female × 1.21 if Black.
Where: sCr = serum creatinine concentration (mg/dl).
This study was approved by our local ethical committee
and all the patients participated in the study after a written
consent.
Statistical Analysis
Variables are given as mean and standard deviation (SD)
unless otherwise stated. T-test, Kruskal-Wallis Test and
Pearson correlation were used as indicated. Multivariate
linear regression analysis was employed to determine the
predictive value of quantitative parameters. A p value ≤
0.05 was viewed as statistically significant with assign-
ment of a borderline of significance when the p value lies
between >0.05 and <0.1, while a non-significant level was
noted as NS. All analysis was performed using the Statisti-
cal Package for Social Science (SPSS) version 10.0.
Results
Thyroid hormone levels
We noted, as seen in table 1, a lower T3 levels in patients
with NTI compared to the corresponding level in control
subjects (0.938 ± 0.477 vs 1.345 ± 0.44 nmol/L) that was
a statistically significant (p = 0.001). Likewise was T4 con-
centrations (47.9 ± 28.41 vs 108 ± 19.49 nmol/L, p <
0.0001). While TSH was significantly lower in NTI
patients (1.08 ± 0.518 vs 1.92 ± 0.93 μIU/L, t test p <
0.001), it was well within the normal reference values of
employed immunoassay (0.49+4.67 μIU/L).
Serum interleukins concentrations
In the same table, IL-6 in NTI was significantly above con-
trols' level (105.18 ± 72.01 vs 3.35 ± 1.18 ng/L, p <
0.00001). Overall, this level is considerably above the sen-
sitivity of the used immunoassay kit and above, as well,
the upper limit of normal reference value (<20 pg/ml).
Similarly, IL-10 was significantly higher above measure-
ments observed in controls (74.13 ± 52.99 vs 2.64 ± 0.92
ng/ml, p < 0.00001). Of note, such concentrations are sig-
nificantly above the upper limit of normal level of the
used kit (<5 pg/ml).
Of note, in order to verify the validity of the data in view
of the high level of the investigated interleukins and to
assess the linearity of the assay, we diluted the samples
with the appropriate Calibrator Diluent to produce sam-
ples with values within the dynamic range of the used
immunoassay.
Relation between thyroid hormones and interleukins 
changes
We observed in NTI patients a significantly negative corre-
lation, using Pearson' correlation coefficient, between IL-
6 and T3 (r = -0.620, p < 0.0001) (figure 1). Similarly was
the correlation existing between IL-6 and total T4 level (r
= -0.267, p < 0.001). Likewise, IL-10 was negatively and
significantly correlated with the lowered T3 in NTI-
patients (r = -0.512, <0.0001) (figure 1) and not with T4
or TSH. Interestingly, both interleukins; IL-6 and IL-10
were positively and significantly correlated (r = 0.770, p =
<0.001) with each other (figure 2).
By linear regression analysis, IL-6 (Unstandardized Coef-
ficient (B) ± Standard Error (SE) = -3.72E-03 ± 0.001, R2 =
0.338, p = 0.001) and not IL-10 (B) ± SE = -7.512E-04 ±
0.001, R2 = 0.338, p = 0.631) was found to be a potential
risk factor that could predict the observed lower circulat-
ing level of T3. However, only a borderline degree of sig-
nificance (B ± SE = -0.144 ± 0.079, R2 = 0.082, p = 0.071)
was seen for IL-6 as a potential predictor of T4 reduction
in NTI. Importantly, IL-10 has not been found to be a
potential predictor for the lower TH concentrations.
Table 1: Comparison between serum T3, T4, TSH, IL-6 and IL-10 levels in the 60 non-thyroidal illness patients and their 20 control 
subjects.
Tested Parameters Non-thyroidal Illness (n = 60) Healthy Controls (n = 20) Significance Level (p Value)
T3 (n mol/L) 0.936 ± 0.47 1.343 ± 0.45 0.001
T4 (n mol/L) 74.90 ± 28.41 108.30 ± 14.50 <0.0001
TSH (μIU/L) 1.078 ± 0.52 1.921 ± 0.93 <0.001
IL-6 (ng/L) 105.18 ± 72.01 3.34 ± 1018 <0.0001
IL-10 (ng/L) 74.33 ± 52.99 2.64 ± 0.92 <0.00001
Out of the investigated 60 patients, four showed a TSH serum level that was below the sensitivity of the used assay (0.06 μIU/L). These patients 
were assumed to have a TSH concentration of (0.06 μIU/L) in order to calculate the mean TSH value.BMC Endocrine Disorders 2008, 8:1 http://www.biomedcentral.com/1472-6823/8/1
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Subgroup analysis
Using ANOVA single-factor test (Kruskall-Wallis test), we
have detected a significant trend in T3 alterations among
the three subgroups of NTI patients and their controls (p
< 0.0001). Approximately, more or less similar level of
significance do exist for total T4 (p < 0.001). Interestingly,
differences in both IL-6 and IL-10 among the 4 subgroups
were significant also (p < 0.00001).
Further, the proportion of patients with T3, total T4, and
TSH levels below normal range was highest in the MI
patients (70%, 70%, and 72%, respectively) who dis-
played the greatest mean concentration of both IL-6 and
IL-10 (192.5 ± 45.1 ng/L & 122.95 ± 46.1 ng/L, respec-
tively) compared with CHF (82.95 ± 28.9 ng/L & 69.05 ±
44.0 ng/L, respectively) and CRI patients (40.05 ± 28.9
ng/L & 30.4 ± 10.6 ng/L, respectively) (table 2). Of note,
the changes in interleukins levels matched the severity of
myocardial damage in MI subgroup of patients as inferred
from the significant correlations observed between the
cardiac enzyme CK-MB isoenzyme and both IL-6 (r =
0.498 and p = 0.025) and IL-10 (r = 0.467 and p = 0.038).
Surprising was our observation that CRI-patients showed
the least disturbance in IL-6 and IL-10 despite the exhibi-
tion of lower than normal levels of T3, T4, and TSH in a
higher proportion of them compared with CHF patients
(40%, 45%, and 26% versus 35%, 25%, and 18%, respec-
tively) (table 2).
Discussion
In the current study, we observed a considerably lower T3
and total T4 concentrations signifying thyroid dysfunc-
tion in patients with variable non-thyroidal illnesses
(NTI) while serum TSH showed a mean value that was not
significantly different from that in controls. Our findings
are in concordance with that noted by Horimoto and co-
workers (1988) [26]and in contrast to the result of a study
undertaken by Kayima and associates (1992) [27]. The
clinically euthyroid patients, are biochemically abnormal
defining the previously described euthyroid sick syn-
drome (ESS) [4,28].
Speculations as to the value of ESS development in
patients with NTI have long been heard. Some investiga-
tors reported a protective function of this phenomenon
[4,14] while others viewed it either as an adaptive
response to reduce tissue energy requirements in face of
systemic illness, or a maladaptive one, that induces dam-
aging tissue hypothyroid [29].
Also, in the study under discussion we detected a substan-
tially high level of the pro-inflammatory cytokine, IL-6 in
NTI patients supporting its possible role as an endocrine
cytokine with a regulatory effect on many endocrine sys-
tems [30], including thyroid gland [31]. We as well
detected a considerably high level of the anti-inflamma-
tory cytokine, IL-10 in NTI-patients. Likewise, Dehoux
and associates (2000) reported its release in response to
stressful situations such as cardiopulmonary bypass [32].
Interestingly, we noticed a positive association between
both IL-6 and IL-10 which accords with a previous notion
[33] and could be attributed to the fact that secretion of
both interleukins is stimulated by the same cytokines such
as TNF-α [34,35]. So, within the cytokine network, activa-
tion of pro-inflammatory mediators such as IL-6 is fol-
lowed by increased production of endogenous inhibitory
molecules including the antagonistic cytokine IL-10 in an
attempt to suppress release of pro-inflammatory
cytokines. This dimorphic response may be related to
macrophages resistance to the suppressive effect of IL-10
as a result of down-regulation of soluble IL-10 receptors
expression [36]. The high IL-10 levels was hoped for to
minimize the deleterious effect of the raised IL-6 [37].
Taniguchi and colleagues (1999) highlighted this poten-
tial protective effect of IL-10 in their 25 patients with sys-
temic inflammatory states [38].
Correlation between IL-6 & IL-10 in the 60 patients with  non-thyroidal illness Figure 2
Correlation between IL-6 & IL-10 in the 60 patients with 
non-thyroidal illness.
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In this study, the suppressed THs were negatively associ-
ated with IL-6 elevations. Boelen and colleagues (1993)
have observed similar correlation in their 100 patients
with NTI during their first day of hospitalization [11].
However, such correlation does not exist for TSH and IL-6
and this was not surprising since TSH was maintained
within the normal reference value. Also, we observed an
inverse association between the high IL-10 and the sup-
pressed TH levels, in contrast to the findings of Guillén
and associates [39]. Dissimilar to IL-6, IL-10 was not
indicative of the observed TH alterations. Our results do
not so support any role for IL-10 in the pathogenesis of
ESS. This is in concordance with what has been noticed by
Boelen and colleagues (1996) [15].
We observed also a highest level of IL-6 along with lowest
measurements of both T3 and T4 in the MI patients while
the least change was noticed in patients with chronic ill-
ness exemplified by CHF. This is in accordance with the
hypothesis that the magnitude of TH alteration parallels
the severity of the associated NTI [40-42]. Similarly, the
considerably increased IL-10 in our MI patients was found
to be linked, at least statistically, to the detected ESS. Such
increase in IL-10 was reported to be beneficial to ICU
patients through improving their outcome [43]. In fact,
Kimur and co-workers (2001) have correlated the
increased IL-6 and IL-10 with TH alterations in their 20
acute MI patients and the time course of both interleukins
and T3 seemed to be tightly linked [44].
The least disturbance in T3, T4, and TSH levels concomi-
tant with the lowest levels of IL-6 and IL-10 were observed
in CHF patients, yet higher than control subjects. This is
more or less similar to the findings of Nishino and associ-
ates (2000) [45] as well as of Davis and colleagues (1996)
although the latter however, have not tested IL-10 [46].
Surprising was our observation that T3 and T4 were con-
siderably low in an appreciable proportion of CRI patients
whilst their serum IL-6 (and IL-10) levels were of lesser
elevations compared to other two subgroups. This might
simply mean that while a probable contributory role for
IL-6 is suggested, it is not the only factor involved in the
pathogenesis of ESS encountered in some specific forms
of NTI such as CRI. Our view is supported by a study done
on 28 patients with CRF in 1994 [18] and another by Boe-
len and colleagues who found that only 28% of T3 levels
variability was accounted for by the circulating IL-6 con-
centrations [11].
From our observations in chronic forms of NTI, we can
suggest that an acute rather than a long-lasting perturba-
tion of IL-6 may be involved in development of ESS. In
accord with our suggestion was the work carried out by
Stouthard and colleagues (1994) who tested the influence
of acute compared to chronic administration of IL-6 on
TH homeostasis [47]. This was further supported by Hash-
imoto and associates (1995) who have demonstrated an
inverse association between IL-6 and TH in their paediat-
ric patients with short-lived illness [48] but not in longer-
lasting diseases [49]. The same holds true for IL-10 that
seems to be only partly involved in this process [32]. The
continuation of the ESS state, as has been postulated by
Docter and associates (1993) [50], would however be
attributed to yet unidentified factors.
Conclusion
We can conclude that euthyroid sick syndrome occurs in
many patients with a wide range of non-thyroidal ill-
nesses in association with an appreciable perturbation in
IL-6 as well as IL-10 and that its pathogenesis might be
regulated by IL-6 with possible involvement of some
other, yet unrecognized, key players in some specific
forms of NTI as chronic renal insufficiency.
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